rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Joshua Hexter

COO & Cbo

Company insider

Files Form 4 as: COO & Cbo, Oramed Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
47
Buys
0
Sells
2
Bought
$0
Sold
$1.4M
Companies
1
Companies where not an officer
0
First trade
14 Apr 2013
Last trade
1 Oct 2026
Last filed
2 Oct 2026

Companies traded

Where they are an officer
ORMP Oramed PharmaceuticalsOfficer · Biotechnology · last 1 Oct 20260 buys · 2 sells

Activity over time

1 Jun – 1 Oct
10Jun 26Jul 26Aug 26Sep 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
1 Oct 2026filed 2 Oct 2026ORMP Oramed PharmaceuticalsBiotechnologySEC FORM 4 Sold$135K30,000 at $4.51filing
24 Sep 2026filed 25 Sep 2026ORMP Oramed PharmaceuticalsBiotechnologySEC FORM 4 Code A—75,455filing
24 Sep 2026filed 25 Sep 2026ORMP Oramed PharmaceuticalsBiotechnologySEC FORM 4 Code A—209,291filing
24 Sep 2026filed 25 Sep 2026ORMP Oramed Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—50,000filing
24 Sep 2026filed 25 Sep 2026ORMP Oramed Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—50,000filing
24 Sep 2026filed 25 Sep 2026ORMP Oramed Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—50,000filing
24 Sep 2026filed 25 Sep 2026ORMP Oramed Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—36,000filing
24 Sep 2026filed 25 Sep 2026ORMP Oramed Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—50,000filing
24 Sep 2026filed 25 Sep 2026ORMP Oramed Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—36,000filing
24 Sep 2026filed 25 Sep 2026ORMP Oramed PharmaceuticalsBiotechnologySEC FORM 4 Code A—75,455filing
24 Sep 2026filed 25 Sep 2026ORMP Oramed PharmaceuticalsBiotechnologySEC FORM 4 Code A—209,291filing
2 Jul 2026filed 2 Jul 2026ORMP Oramed PharmaceuticalsBiotechnologySEC FORM 4 Code M$185K50,000 at $3.69filing
2 Jul 2026filed 2 Jul 2026ORMP Oramed Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—50,000 at $0.00filing
2 Jul 2026filed 2 Jul 2026ORMP Oramed Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—50,000 at $0.00filing
2 Jul 2026filed 2 Jul 2026ORMP Oramed PharmaceuticalsBiotechnologySEC FORM 4 Code M$185K50,000 at $3.69filing
1 Jul 2026filed 2 Jul 2026ORMP Oramed PharmaceuticalsBiotechnologySEC FORM 4 Sold$611K137,000 at $4.46filing
1 Jul 2026filed 2 Jul 2026ORMP Oramed PharmaceuticalsBiotechnologySEC FORM 4 Sold$611K137,000 at $4.46filing
17 Mar 2026filed 18 Mar 2026ORMP Oramed PharmaceuticalsBiotechnologySEC FORM 4 Code A—95,889 at $0.00filing
17 Mar 2026filed 18 Mar 2026ORMP Oramed PharmaceuticalsBiotechnologySEC FORM 4 Code A—95,889 at $0.00filing
22 Jan 2026filed 29 Jan 2026ORMP Oramed PharmaceuticalsBiotechnologySEC FORM 4 Code M—19,000 at $0.00filing

Sectors

Health Care2

Buys in green, sells in red, by the company’s sector.

Related people

Avraham GabayChief Financial Officer · Chief Financial Officer at Oramed Pharmaceuticals, filing Form 4 there in the last year
Nadav KidronPresident and CEO · President and CEO at Oramed Pharmaceuticals, filing Form 4 there in the last year
Miriam KidronChief Scientific Officer · Chief Scientific Officer at Oramed Pharmaceuticals, filing Form 4 there in the last year
Arie MayerDirector · Director at Oramed Pharmaceuticals, filing Form 4 there in the last year
Benjamin ShapiroDirector · Director at Oramed Pharmaceuticals, filing Form 4 there in the last year